만성폐쇄성폐질환과 천식을 감별 진단하는데 기관지확장제 가역성 검사의 역할

Abstract

BACKGROUND: Although bronchodilator reversibility testing is widely performed to diagnose asthma or COPD, there is debate upon its usefulness and methods to differentiate asthma from COPD. The purpose of this study is to elucidate the role of bronchodilator reversibility testing in differentiating asthma from COPD and to confirm which method is better at evaluating bronchodilator reversibility.

METHODS: 26 asthma patients and 31 COPD patients were reviewed retrospectively. Spirometry was performed before and after bronchodilator inhalation to get FEV1, FVC. To evaluate bronchodilator reversibility, the increase in FEV1 or FVC was expressed as three methods, ´percentage of the baseline value´, ´percentage of the predicted value´, or ´absolute value´. Area under the ROC curve was measured to compare the three methods. In addition, the criteria of American Thoracic Society (ATS) for bronchodilator reversibility were compared to those of European Respiratory Society (ERS).

RESULTS: 1.In differentiating asthma from COPD, ´percentage of the predicted value´, or ´absolute value´ method was useful but ´percentage of the baseline value´ was not. However, the ability to differentiate was weak because areas under the ROC curves by all methods were less than 0.75. 2.The criteria of ERS were superior to those of ATS for bronchodilator reversibility to differentiate asthma from COPD because likelihood ratio (LR) of a positive test by ERS criteria was greater than ATS criteria and because LR of a negative test by ERS criteria was less than ATS criteria.

CONCLUSION: In differentiating asthma from COPD, bronchodilator reversibility testing has a weak role and should be considered as an adjunctive test.